'Sticky' speech and other evocative words may improve language

New study finds that iconicity in parents' speech helps children learn new words

2021-05-17

(Press-News.org) Some words sound like what they mean. For example, "slurp" sounds like the noise we make when we drink from a cup, and "teeny" sounds like something that is very small. This resemblance between how a word sounds and what it means is known as iconicity.

In her lab at the University of Miami, Lynn Perry, an associate professor in the College of Arts and Sciences Department of Psychology, previously found that children tend to learn words higher in iconicity earlier in development then they do words lower in iconicity. She also found that adults tend to use more iconic words when they speak to children than when they speak to other adults.

"That got us curious about why," said Stephanie Custode, a doctoral student in psychology, who worked with Perry to answer questions posed by her prior work. "Does iconicity play a causal role in children's language development, helping them learn new words, eventually even those words that have non-iconic, or arbitrary, sound-meaning associations?"

For their new study, published in the journal END

ELSE PRESS RELEASES FROM THIS DATE:

Warnings on the dangers of screen time are ill founded -- New study

2021-05-17

University researchers have carried out the largest systematic review and meta-analysis to date of how people's perceptions of their screen time compare with what they do in practice, finding estimates of usage were only accurate in about five per cent of studies. The international team say this casts doubt on the validity of research on the impact of screen time on mental health, and its influences on government policy, as the vast majority rely on participants to estimate (self-report) how long they spend on digital devices, rather than logs of actual usage, or tracked time. "For decades, researchers have relied on estimates of how we use various technologies to study how people use digital ...

Mammals in the time of dinosaurs held each other back

2021-05-17

A new study led by researchers from the Oxford University Museum of Natural History, University of Oxford and the University of Birmingham for Current Biology has used new methods to analyse the variability of mammal fossils, revealing extraordinary results: it was not dinosaurs, but possibly other mammals, that were the main competitors of modern mammals before and after the mass extinction of dinosaurs. The study challenges old assumptions about why mammals only seemed to diversify, becoming larger and exploring new diets, locomotion and ways of life, after the extinction of the non-bird dinosaurs. It points to a more complex story of competition between distinct mammal groups. ...

Routine testing before surgery remains common despite low value

2021-05-17

Before undergoing surgery, patients often go through a number of tests: blood work, sometimes a chest X-ray, perhaps tests to measure heart and lung function. In fact, about half of patients who had one of three common surgical procedures done in Michigan between 2015 and the midway point of 2019 received at least one routine test beforehand. That's according to new research in JAMA Internal Medicine from a collaboration between the University of Michigan-based Michigan Program on Value Enhancement (MPrOVE) and the Michigan Value Collaborative, a statewide initiative that focuses on improving medical and surgical quality. Yet plenty of evidence suggests that preoperative testing is often unnecessary ...

Omecamtiv Mecarbil brings greater benefits for severe heart failure

2021-05-17

The experimental heart failure drug omecamtiv mecarbil reduced heart failure hospitalizations by a greater margin among patients with more severely reduced ejection fraction, a measure indicating severe impairment in the heart's pumping ability, compared with those who had moderately reduced ejection fraction, according to research presented at the American College of Cardiology's 70th Annual Scientific Session. Omecamtiv mecarbil works by improving the ability for heart muscle cells to contract and operates through a different biological pathway than any of the current heart failure medications. The research ...

Rare COVID-19 response in children explained

2021-05-17

One of the enduring mysteries of the COVID-19 pandemic is why most children tend to experience fewer symptoms than adults after infection with the coronavirus. The immune system response that occurs in the rare cases in which children experience life-threatening reactions after infection may offer an important insight, a Yale-led study published in the journal Immunity suggests. While many children infected with the virus are asymptomatic or go undiagnosed, about one in 1,000 children experience multi-system inflammatory response (MIS-C) four to six weeks after confirmed infection with SARS-CoV-2, the virus that causes COVID-19. The condition ...

An asthma vaccine effective in mice

2021-05-17

Inserm teams led by Laurent Reber (Infinity, Toulouse) and Pierre Bruhns (Humoral Immunity, Institut Pasteur, Paris) and French company NEOVACS have developed a vaccine that could induce long-term protection against allergic asthma, reducing the severity of its symptoms and thus significantly improving patient quality of life. Their research in animals has been published in the journal Nature Communications. Asthma is a chronic disease affecting around 4 million people in France and 340 million worldwide. Allergic asthma is characterized by inflammation of the bronchial tubes and respiratory discomfort caused by the inhalation of allergens, most often dust mites. This exposure to dust mites and other allergens leads to ...

Clinical trial suggests convalescent plasma may improve survival with severe COVID-19

2021-05-17

A randomized double-blind controlled trial of convalescent plasma for adults hospitalized with severe COVID-19 found that mortality at 28 days in the treatment arm was half the rate seen in the control arm (12.6% vs. 24.6%), although treatment was not associated with other improvements in clinical status. The study was led by investigators from the Center for Infection and Immunity at Columbia University Mailman School of Public Health; Columbia University Irving Medical Center; ICAP at Columbia University; Instituto Nacional de Infectologia and Hospital Federal dos Servidores do Estado in Rio de Janeiro, Brazil; University of Washington; and New York Blood Center. The results are published in the Journal of Clinical Investigation. According ...

Pirfenidone reduces scar tissue in patients with heart failure

2021-05-17

Patients with heart failure with preserved ejection fraction who took the antifibrotic drug pirfenidone saw a significant reduction in a marker of heart muscle scarring compared with patients who received a placebo, based on findings from an early-phase trial presented at the American College of Cardiology's 70th Annual Scientific Session. "Observational data suggests that heart muscle scarring, or fibrosis, is an important disease process for heart failure prognosis," said Chris Miller, MD, a cardiologist and National Institute for Health Research Clinician Scientist at the University ...

Sacubitril/valsartan not superior to valsartan for advanced heart failure

2021-05-17

Patients with heart failure with reduced ejection fraction (HFrEF) did not have better health outcomes if they took sacubitril/valsartan combination therapy compared with valsartan alone, according to new data presented at the American College of Cardiology's 70th Annual Scientific Session. Heart failure, a leading cause of hospitalization among adults over age 65, is a condition in which the heart becomes too weak to pump blood effectively to the rest of the body, causing fatigue and shortness of breath. For patients with severe heart failure, treatment options are limited to a mechanical heart pump or heart transplant. Doctors have sought ways to slow the progression of severe heart failure ...

How COVID-19 survival improved in UK hospitals during first wave

2021-05-17

The likelihood of people surviving COVID-19 in UK hospitals has been improving over time, a new study has found. Research published in The Lancet Respiratory Medicine by the ISARIC Coronavirus Clinical Characterisation Consortium found that in-hospital mortality declined from 32% at the start of the first wave (Mar-Apr 2020) to 16% at the end of the first wave (Jun-Jul 2020). In their study of 63,972 adults admitted to 247 UK hospitals the researchers found reductions in mortality were observed in all age groups, in all ethnic groups, for both sexes, and in patients with and without comorbidities. This improvement was ...

Inhibition of cyclooxygenase-2 upregulates the nuclear factor erythroid 2-related factor 2 signaling pathway to mitigate hepatocyte ferroptosis in chronic liver injury

'Sticky' speech and other evocative words may improve language

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: